INTRODUCTION
Chronic myeloid leukemia (CML) is caused by a unique genomic abnormality, which is the reciprocal translocation between chromosomes 9 and 22 (Philadelphia chromosome-positive, Ph þ ), leading to the formation of a new bcr-abl fusion gene (BCR-ABL1) that codes for a constitutively activated, cytoplasmlocated tyrosine kinase (TK). 1 The natural progression of the disease towards accelerated and blastic phases (AP, BP) resulted in the death of almost all patients in o10 years, when treated with conventional chemotherapy, like busulfan and hydroxyurea. 2, 3 As some patients died in months and others lived 410 years, several studies tried to identify which factors had a prognostic value as a guide to the choice of treatment. In the era of conventional chemotherapy, the Sokal risk score 4 was developed, became rapidly popular and was internationally accepted. In the era of interferon-alfa (IFN-a), the Euro risk score 5 was developed and established. Then, the introduction and rapid application of imatinib, the first of a class of tyrosine kinase inhibitors (TKI), revolutionized the treatment results to such a point that overall survival (OS) rose above 80% at 5 years and to plateau thereafter, approaching the survival probabilities of non-leukemic individuals. [6] [7] [8] [9] Sokal and Euro scores were also applied to patients who were treated first-line with imatinib. [10] [11] [12] [13] [14] [15] [16] The establishment of an European CML Registry, based on the EUTOS project (European Treatment and Outcome Study for CML) of the European Leukemia Network, made it possible to analyze a large multicenter series of patients in terms of prognosis and outcome. The patients had been enrolled in prospective studies of treatment with imatinib-based regimes. 17 The risk score that was generated by this analysis predicted the achievement of a complete cytogenetic response (CCyR) within 18 months of imatinib treatment, and with survival free from progression to AP or BP (progression-free survival, PFS). 17 The EUTOS risk score predicted CCyR and PFS better than the Sokal or Euro score. Being based only on spleen size and blood basophil percentage assessed at baseline prior to any treatment and resulting in only two risk groups, the new EUTOS score was even simpler than the prior scores:
EUTOS score ¼ 7 Â Basophils þ 4 Â Spleen size Basophils are measured in percentage in the peripheral blood. Spleen is measured in centimeters, maximum distance below the costal margin, by manual palpation. All measurements need to be performed before any therapy. If the value of the EUTOS score is p87, the patient is allocated to the low-risk group. Patients with a score above 87 belong to the high-risk group. To develop the EUTOS risk score, a particularly cautious procedure was adopted: the registry cases were divided into two groups, one of which was used to develop the score (learning sample) and the other to validate the score (validation sample). 17 However, all the data that were used to generate the EUTOS risk score were obtained from patients enrolled in prospective studies of treatment. It is generally acknowledged that patients who are enrolled in such studies, though numerous and well studied, cannot represent a universally reliable sample of all patients with CML, with many patients cared for and managed outside such studies. 18 We report here the validation of the new EUTOS risk score, based on an independent data set of Ph and/or BCR-ABL1 þ patients in chronic phase who were treated first-line with imatinib-based regimes, registered at different centers in different countries and outside prospective studies of treatment.
PATIENTS AND METHODS

Study population
The EUTOS CML registry is divided into two sections. Both sections include patients aged 18 years or older and diagnosed with Ph and/or BCR-ABL1 þ CML in chronic phase during the years 2002-2006. All patients were treated with imatinib-based regimes, and the treatment was started within 6 months after diagnosis. The so-called 'in-study' section provided data of 2060 patients who were enrolled in prospective, Good Clinical Practiceoperated studies of frontline therapy. The data of the in-study section were employed to develop the EUTOS risk score. 17 The second section provided data of 1288 'out-study' patients who were not enrolled in prospective Good Clinical Practice studies but were registered prospectively at the respective National Study Groups. The data of the out-study section were employed in the analysis presented here.
The out-study patients were collected from a hospital-based National Group located in Madrid (n ¼ 193), from the National Polish Registry , but all registries have acknowledged a possible selection by age, with an under-representation of old patients. These 1288 patients who were registered in the out-study section of the registry were not always monitored as regularly as the patients who were registered in the in-study section and used to develop the EUTOS risk score. In particular, only 616 of the 1288 out-study patients had a cytogenetic test at or around 18 months (18 ± 6), whereas 1251 patients had the baseline data necessary for the calculation of the risk score (basophils and spleen). Of those, 1190 patients had the follow-up data necessary for the calculation of the survival outcomes (OS and PFS). An overview of the patient data available for the different analyses is given in Figure 1 .
Definitions
The criteria recommended by the European Leukemia Network 7, 8 were used for the definitions of CCyR (no Ph þ metaphases out of at least 20 banded marrow cell metaphases). Times to CCyR, PFS and OS were calculated from the start of imatinib therapy.
Statistical analyses
Sensitivities, specificities and positive predictive values were used to evaluate the accuracy of the score. The w 2 test was used for comparison of proportions, and Wilson score confidence intervals (CIs) were calculated to indicate the reliability of proportion estimates.
For the analyses of OS and PFS, Kaplan-Meier curves were calculated. To quantify differences in survival probabilities, the log-rank test was used.
For the landmark analysis of the 18-month cutoff, the Kaplan-Meier curves were modified. Up to the cutoff at 18 months, PFS was estimated for both groups together. Under consideration of the PFS probability at 18 months, after 18 months, PFS was estimated separately for the low-and high-risk groups. Accordingly, the log-rank test was applied to assess the differences between the two groups from 18 months onwards.
A cumulative incidence curve including respective CIs was calculated to analyze time to CCyR. Death was considered as a competing risk. Thus, the Gray test was used for group comparisons. 19, 20 Level of significance was P ¼ 0.05. Calculations were carried out using SAS Version 9.2 software (Cary, NC, USA).
Data collection, processing and all statistical analyses were exclusively carried out by the Central Data Center at the Department for Medical Information Sciences, Biometry, and Epidemiology of the LudwigMaximilians-Universität in Munich, Germany.
RESULTS
Registry eligibility criteria were met by 1288 patients. Baseline characteristics of the patients are reported in Table 1 , where they are compared with the baseline characteristics of the in-study patients whose data were used to develop the EUTOS score. 17 The laboratory values were almost identical. However, differences with regard to gender (male individuals 52% vs 60%), age (median 48 vs 52 years), spleen size (median 2 cm below costal margin vs 1 cm), frequency of high-risk cases (12.5% vs 10.5%) and the observation time (median 65 vs 42 months) were noticed. All patients were treated initially with imatinib, either at the standard dose of 400 mg daily or at a higher dose of 600-800 mg daily. Less than 1% of the patients were treated initially with imatinib plus other agents.
The EUTOS score was originally developed to predict the probability of being in CCyR after 18 months of imatinib because the patients who do not achieve that response are considered subject to treatment failure and are in need of other treatments. Figure 1 . Visualization of patient data available for the different analyses. As patients with progression or PFS status censored within the first 18 months could be used for the landmark analysis, patient number was higher in the landmark analysis than for analysis of CCyR status at 18 months only.
Therefore, the first step of this analysis was to check whether that assumption was valid also in this series of out-study patients. The probability of PFS up to 18 months was 92.8%. Based on the cytogenetic response at 18 months, the landmark analysis of PFS from 18 months resulted in significantly different PFS (Po0.0001, Figure 2 ) and thus, confirmed the prognostic value of CCyR. At 5 years, PFS was 88.3% (95% CI 85.9-90.2%) in the low-risk group and only 79.4% (95% CI 73.4-84.6%) in the high-risk group. Then, the EUTOS risk score was calculated in all 1251 patients with the required baseline data (spleen and basophils) available. The number of high-risk patients, with a score higher than 87, was 161 (12.5%).
In the high-risk patients, the cumulative incidences of ever achieving a CCyR over the whole observation time were significantly lower than in the low-risk patients (Po0.0001), with 67.6% (95% CI 59.1-74.7) vs 84.4% (95% CI 82.1-86.7%) at 5 years, respectively ( Figure 3) .
Data on CCyR status after 18 months of therapy were available for 616 patients, 75 (12.2%) of whom were in the high-risk group. Sensitivity and specificity of the EUTOS score were 16.6% and 89.6%, respectively, which were comparable to the results of the in-study data (21% and 92%, respectively). The probability of being in CCyR after 18 months was 61.3% for patients in the highrisk group and 73.0% for patients in the low-risk group.
Next, high-risk and low-risk patients were compared in terms of survival times. PFS differed significantly between the EUTOS highand low-risk groups (P ¼ 0.0395). After 5 years, a period of time that corresponds to the median observation time of the patients (65 months for PFS), PFS was 89.3% (95% CI 87.1-91.1%) in the low-risk patients vs 82.0% (95% CI 74.7-87.3%) in the high-risk ones (Figure 4) . OS after 5 years was 90.5% (95% CI 88.4-92.2%) in low-risk patients vs 83.3% (95% CI 76.3-88.5%) in the high-risk group. Survival probabilities of the groups differed significantly with a P-value of the log-rank test of 0.0278 ( Figure 5 ). Interestingly, the curves of PFS and OS look as if they would diverge more in the first 5 years than later, which is in agreement with many prior observations that most progressions occur during the first years of imatinib therapy. After 5 years, there is a tendency of a plateau. [6] [7] [8] [9] 13, 14 A comprehensive comparison of the results of the application of the EUTOS risk score in the original series of in-study patients and in the present, independent and different series of out-study patients is reported in Table 2 . The figures cannot be identical, but Reported as cm below the costal margin as assessed by palpation. 
DISCUSSION
The prognosis of many hematologic malignancies has evolved from a gross evaluation of leukemic or tumor cell mass, as expressed, for example, by the leukocyte count, to a more sophisticated molecular analysis of the genome. Today, not only the prognosis, but also the intensity of the treatment, and, more importantly, the choice of the treatment, is based on the biological characteristics of the disease, as assessed by molecular techniques that can lead to the identification of targetable molecular abnormalities. In CML, the genetic instability of Ph þ cells leads almost always to other genomic alterations that drive the disease to progression. Identifying these abnormalities and detecting them before progression has started, possibly at diagnosis, is likely to be necessary and important to improve prognostic evaluation and to fine tune targeted therapy. A prognostic value has been assigned to the expression and the polymorphisms of several genes, such as those involved in multidrug resistance, 21-25 the OCT-1 system 26-29 and the apoptotic system, 30, 31 to the type of transcript, [32] [33] [34] [35] to the baseline level of the transcript, 36, 37 to variant translocations 38 and to clonal chromosome abnormalities in Ph þ cells (CCA/Ph þ ). 39, 40 However, with the possible exception of CCA/ Ph þ , the so-called major route, 39 the data are not yet mature and a prognostic application cannot be universally recommended.
Therefore, the prognostic assessment of Ph þ CML at diagnosis is still based on few, simple, clinical and hematological factors like age, spleen size, platelet count and percentages of myeloblasts, eosinophils and basophils in peripheral blood. The Sokal risk score was proposed in 1984 and was based on patients treated with conventional chemotherapy. 4 The Euro risk score was proposed in 1998 and was based on patients treated with IFN-a. 5 Both risk scores have been applied to imatinib-treated patients, among whom it was found that the high-risk patients responded cytogenetically and molecularly less well. So far, a difference in clinical outcomes (PFS and OS) was reported rarely.
12-14 Moreover, with second-generation TKI, dasatinib and nilotinib, it has been found that high-risk patients responded less well, but no data on clinical, long-term survival outcomes have been reported as yet. 15, 16 The EUTOS score was developed and proposed in 2011, 17 based on a multicenter, multinational series of more than 2000 European patients who were treated first-line with imatinib-based regimes in prospective clinical trials. In these patients, the new EUTOS risk score predicted both the probability of achieving a CCyR and the probability of being alive and progression-free better than the two old scores, also showing that age was no prognostic factor for response in imatinib-treated patients. The advantage over the other two risk scores was significant. It may Abbreviations: CCyR, cytogenetic response; EUTOS, European Treatment and Outcome Study for CML. Notice that in-study patients were enrolled in prospective studies of treatment, whereas out-study patients were registered outside prospective studies, at different centers and in different countries.
Validation of the EUTOS score VS Hoffmann et al not look outstanding, but with the great therapeutic efficacy of imatinib, the discrimination of a high percentage of patients failing to respond can fortunately be regarded as history. The relationship of spleen and basophils with prognosis is firmly established, 4, 5, 17, 41 but the biological meaning of that relationship is still obscure. In CML, basophils are morphologically abnormal, and a high basophil percentage (420%) has been considered a characteristic of acceleration since many years. 42 Still, this is not sufficient to explain why basophil percentage at diagnosis is so important. Spleen may provide an alternative hemopoietic niche to Ph þ cells, 43, 44 and it was reported years ago 45 that Ph þ spleen cells had more CCA/Ph þ than marrow cells, but again this is not sufficient to explain why the size of the spleen is so important that even manual palpation is exact enough for the assessment.
Since the first EUTOS report, 46 the prognostic value of the new score was tested in at least eight independent studies, involving more than 1800 patients treated first-line with imatinib at different doses (400 or 6-800 mg/day), [47] [48] [49] [50] [51] [52] [53] with imatinib 400 mg/day in combination with IFN-a or low-dose arabinosyl cytosine, 54 and also with second-generation TKIs. 53, 55 These patients were recruited or registered in prospective or retrospective, singlecenter or multicenter studies in Europe, the Americas and Asia. The results of these studies are reported in Table 3 . Surprisingly, only two of these studies calculated and reported the probability of being in CCyR at 18 months, which was the first reference point of the EUTOS risk score. The score was tested for different markers of response and different outcomes, at different time points. One study did not find a significant prognostic value, 47 whereas the other seven studies found a prognostic value for CCyR and major molecular response (Table 3) . Of the seven studies reporting results on OS and PFS, five studies found differences between risk groups, four of them with P-values below the level of significance (0.05). Detecting a prognostic value with a high level of significance was always more frequent for the cytogenetic and molecular markers of the outcome than for long-term outcomes of PFS and OS themselves (Table 3 ). This was not surprising because the proportion of high-risk patients was small (median 9.6%, range 5.1 55 to 31% 51 ) , and the number of events that were counted for the outcomes, deaths and progressions, was also small, which was due to the efficacy of first-and second-line treatments. It is of interest to see that the EUTOS risk score was particularly significant also in patients of Asian origin 50, 51 who could have other reasons of resistance to imatinib, based on a different ethnical distribution of some polymorphisms that affect the sensitivity to the drug. 30 The EUTOS risk score was originally developed because it was believed that the prognosis of TKI-treated patients should have no longer been based on prognostic systems that were derived from patients treated with conventional chemotherapy or IFN-a, and because it was found that the three risk groups defined according to Sokal or Euro did not discriminate intermediate-risk patients from low-and high-risk patients, respectively. 17 Moreover, age, that was an important risk determinant for Sokal and Euro scores, was no longer prognostically important for the course of disease in imatinib-treated patients. Thus, there is no reason to limit the use of imatinib for elderly patients.
The EUTOS risk score represents the continuation of a process of optimization that was based on simple, even naive, clinical and hematologic factors. The EUTOS score has now been validated in many independent studies. In the era of molecular hematology, this may be seen as puzzling or even frustrating, but until new, biological factors are identified and validated-including particularly the gene expression profile 56, 57 -it will be difficult to improve further on the prognostic assessment of CML before a treatment is initiated. It is well recognized that the outcome can be predicted even better once the early response to a given treatment becomes evaluable, 7, 8, [12] [13] [14] 58, 59 but a baseline assessment of Table 3 . The EUTOS risk score was tested for prognosis in eight independent studies with a total of 1801 newly diagnosed patients in Europe, 47, 48, 52, 55 the Americas, 49, 53 and Asia
50,51
Marin et al. 47 Jabbour et al. 53 Breccia et al. 48 Castagnetti et al. 55 Pagnano et al. 49 Tribelli et al. 52 Than et al. 51 Yahng et al. 11.2% (31) 8.2% (38) 9.6% (20) 5.1% (11) 13.2% (21) 6.4% (17) 31% (43) 16.5% ( Abbreviations: AP, accelerated phase; BP, blastic phase; CCyR, cytogenetic response; EUTOS, European Treatment and Outcome Study for CML; MMR, major molecular response; OS, overall survival; PFS, progression-free survival; TKI, tyrosine kinase inhibitor. First-line treatment was imatinib, dose not reported in three studies; 47, 48, 50 Imatinib 400 mg/day; 51, 52 Imatinib 400 mg/day (91%) and 800 mg/day (9%); 49 Imatinib 400 mg/day (15%) or 800 mg/day (45%), or dasatinib (19%), or Nilotinib (21%); 53 Nilotinib 800 mg/day. 55 Relationships among EUTOS risk score and the clinical outcomes (high risk vs low risk), as they were evaluated at different time points. For PFS, events were death from any cause, AP or BP, whichever came first. For OS, events were death from any cause. n.s. for not significant (P-values not specified). 
